“The Part That Died”
Editor's Note: Patient Worthy is pleased to share this article from our friends at Elephants & Tea, originally written by Cecily Liu. To see the article in its original format,…
Continue Reading
“The Part That Died”
EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma
As reported by PharmaBiz, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion supporting Orphan Drug Designation (ODD) for BioInvent’s BI-1808, an investigational anti-TNFR2…
Continue Reading
EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma
New Liposomal Chemotherapy Agent Shows Breakthrough Potential Against Resistant Tumors
As reported on World Pharma News, a collaborative research team from the Medical University of Vienna, HUN-REN Research Centre for Natural Sciences, and Eötvös Loránd University has unveiled a promising…
Continue Reading
New Liposomal Chemotherapy Agent Shows Breakthrough Potential Against Resistant Tumors
Merck’s Welireg Shows Promise in Kidney Cancer Across Two Major Trials
Merck & Co. announced positive results from two Phase 3 studies of its kidney cancer drug Welireg, signaling potential expansion into earlier stages of disease. As reported on BioPharmaDive, in…
Continue Reading
Merck’s Welireg Shows Promise in Kidney Cancer Across Two Major Trials
Danny Gereg Shares His Bladder Cancer Story
We're honored to bring you this video, shared with us by Danny Gereg, that details some of his journey living with bladder cancer. Danny has stayed resilient and positive, finding…
Continue Reading
Danny Gereg Shares His Bladder Cancer Story
How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer
Author's Note: Patient Worthy began following Natera following their presentation at the American College of Medical Genetics conference many years ago. Natera has been known for its advances in prenatal…
Continue Reading
How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer
An Overview on Bladder Cancer
Genetics: a cosmic role of the dice that plays a role in so many medical conditions, including bladder cancer. Mutations in FGFR3, PIK3CA, KDM6A, and TP53 are commonly associated with bladder cancer, but…
Continue Reading
An Overview on Bladder Cancer
New Epigenetic Editing Platform Enhances T Cell Therapies Without DNA Damage
A collaborative team from Arc Institute, Gladstone Institutes, and UCSF has unveiled a groundbreaking epigenetic editing platform that could revolutionize next-generation cell therapies. Published in Nature Biotechnology on October 21,…
Continue Reading
New Epigenetic Editing Platform Enhances T Cell Therapies Without DNA Damage
The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML
Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network. Based on…
Continue Reading
The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML
UChicago Medicine Launches Same-Day Breast Biopsy Program to Accelerate Cancer Diagnosis
In a groundbreaking move to reduce the emotional toll and diagnostic delays associated with breast cancer detection, the University of Chicago Medicine has introduced BIOPSY NOW, a patient-centered initiative offering…
Continue Reading
UChicago Medicine Launches Same-Day Breast Biopsy Program to Accelerate Cancer Diagnosis
“A Letter to My 2020 Self”
Editor's Note: Patient Worthy is proud to share this blog post by Carmen D., a cancer survivor and affectionately known as The Chemo Diva. To see the article in its…
Continue Reading
“A Letter to My 2020 Self”
Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint
Astellas Pharma Inc. has announced that its Phase 2 GLEAM trial evaluating zolbetuximab in combination with gemcitabine plus nab-paclitaxel for metastatic pancreatic adenocarcinoma did not meet its primary endpoint of…
Continue Reading
Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint
“My Own Worst Enemy” – Anna’s Experience with Hodgkin Lymphoma
Editor's Note: Patient Worthy is honored to share this article from our friends at Elephants & Tea. To see the article in its original form, please click here. Dear Cancer,…
Continue Reading
“My Own Worst Enemy” – Anna’s Experience with Hodgkin Lymphoma
Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples
Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…
Continue Reading
Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples
Kaye Lynn VanAntwerp’s Fiery Battle Against Metastatic Colorectal Cancer
My story is like so many other's stories: healthy, semi-young, active, usually chose the salad over the fries, parked farther away in the parking lot to get some extra steps…
Continue Reading
Kaye Lynn VanAntwerp’s Fiery Battle Against Metastatic Colorectal Cancer
Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have announced promising Phase 3 trial results for Datroway, their investigational antibody-drug conjugate (ADC) targeting triple-negative breast cancer (TNBC). The trial demonstrated that Datroway significantly slowed…
Continue Reading
Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer
Finding Strength in Connection: How Breast Cancer Support Communities Are Transforming Patient Care
When a woman hears the words, “You have cancer,” her world shifts in an instant. The journey ahead—marked by treatment, uncertainty, and emotional upheaval—can feel isolating, even for the strongest…
Continue Reading
Finding Strength in Connection: How Breast Cancer Support Communities Are Transforming Patient Care
Advancing Breast Cancer Treatment: AI-Powered Personalization in Neoadjuvant Therapy
Neoadjuvant therapy, which involves administering treatment before surgery to shrink tumors, has become a cornerstone in breast cancer management. Yet, despite its promise, current clinical decision-making often relies on a…
Continue Reading
Advancing Breast Cancer Treatment: AI-Powered Personalization in Neoadjuvant Therapy
Early Research on Two Tough Cancers
Pancreatic cancer took Alex Trebek, Michael Landon, Ruth Bader Ginsburg, Luciano Pavarotti, Steve Jobs, Patrick Swayze, and my dear friend Amy. Glioblastoma (GBM) took Senators John McCain and Ted Kennedy,…
Continue Reading
Early Research on Two Tough Cancers
The Unspoken Guilt of Living
Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea. To see the article in its original form, please click here. Original author…
Continue Reading
The Unspoken Guilt of Living
Rare Cancer Explorer 1.0 (RaCE 1.0): A Game-Changer for Integrative Rare Cancer Research
Rare cancers, defined by their low incidence, collectively constitute nearly a quarter of all cancer diagnoses in the US and Europe, and represent a significant public health challenge. Despite their…
Continue Reading
Rare Cancer Explorer 1.0 (RaCE 1.0): A Game-Changer for Integrative Rare Cancer Research
New Genomic Insights Reveal Unique CLL Patterns in African American Patients
Recent research has brought to light striking genetic differences in chronic lymphocytic leukemia (CLL) among African American (AA) patients, suggesting that their disease may follow a distinct course compared to…
Continue Reading
New Genomic Insights Reveal Unique CLL Patterns in African American Patients
Jazz Pharmaceuticals Secures Historic FDA Approval for First CNS Glioma Therapy
Jazz Pharmaceuticals plc has taken a major leap in rare cancer treatment with the recent FDA accelerated approval of Modeyso (dordaviprone), the first-ever therapy for relapsed H3 K27M-mutated diffuse midline…
Continue Reading
Jazz Pharmaceuticals Secures Historic FDA Approval for First CNS Glioma Therapy
Jhonnatan’s Fight Against Gastric Cancer
Jhonnatan's recent journey with gastric cancer at age 36 ignited a passion within him to share his story and advocate for others. What began as a personal effort to keep…
Continue Reading
Jhonnatan’s Fight Against Gastric Cancer
Unlocking Personalized Immunotherapy: New Immune Biomarkers Identified in Pediatric Germ Cell Tumors
A groundbreaking study from the Molecular Oncology Research Center at Hospital de Amor in Barretos, Brazil, is paving the way for more personalized and less toxic treatments for children with…
Continue Reading
Unlocking Personalized Immunotherapy: New Immune Biomarkers Identified in Pediatric Germ Cell Tumors
